micro-community-banner
 
  • Saved

1yr
A review of the mechanisms of abnormal ceramide metabolism in type 2 diabetes mellitus, Alzheimer's disease, and their co-morbidities - PubMed

A review of the mechanisms of abnormal ceramide metabolism in type 2 diabetes mellitus, Alzheimer's disease, and their co-morbidities - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38379904/

The global prevalence of type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) is rapidly increasing, revealing a strong association between these two diseases. Currently, there are no curative medication...

This paper explores the role of ceramide metabolism in the pathogenesis of type 2 diabetes mellitus and Alzheimer's disease, highlighting its potential as a therapeutic target for their comorbidity treatment.

  • Saved

1yr
Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists - PubMed

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38275636/

Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated with various complications, including cardiovascular diseases. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists...

This review explores the cardiovascular benefits of SGLT2 inhibitors and GLP1 receptor agonists in Type 2 diabetes, highlighting their mechanisms and emerging evidence for improving heart health beyond glucose control.

  • Saved

1yr
Use of Voice-Based Conversational Artificial Intelligence for Basal Insulin Prescription Management Among Patients With Type 2 Diabetes: A Randomized Clinical Trial - PubMed

Use of Voice-Based Conversational Artificial Intelligence for Basal Insulin Prescription Management Among Patients With Type 2 Diabetes: A Randomized Clinical Trial - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38039007/

ClinicalTrials.gov Identifier: NCT05081011.

A voice-based AI application significantly improved insulin titration speed, adherence, glycemic control, and reduced emotional distress in type 2 diabetes patients compared to standard care, suggesting its potential in medication management.

  • Saved

1yr
Management of type 2 diabetes in the new era - PubMed

Management of type 2 diabetes in the new era - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37700155/

Management of type 2 diabetes requires a holistic approach and recent breakthroughs are expected to improve the quality of care.

Advances in type 2 diabetes management emphasize cardiovascular risk stratification, with GLP-1 receptor agonists, SGLT-2 inhibitors, emerging gut hormone therapies, and evolving glucose sensor technologies enhancing holistic patient care.

  • Saved

1yr
Exploring Advances in Psychopharmacology at the NEI Annual Conference

In this video, Dr. David Goodman, an NEI faculty member and Johns Hopkins expert, explores the latest advancements in psychopharmacology presented at the 2024 NEI Annual Conference. Key highlights include the emerging role of GLP-1 receptor agonists in managing diabetes and their potential to address brain inflammation. Dr. Goodman also discusses innovative treatments for ADHD and Alzheimer’s, as well as groundbreaking research into intracellular processes like mTOR pathway modulation. These insights equip physicians with actionable strategies to enhance the precision and efficacy of neurological and psychiatric care.